文献速递胸部肿瘤

第八版肺癌TNM分期系统的验证研究

Validation of the Eighth Edition TNM Lung Cancer Staging System.
PubMed 文献 · J Thorac Oncol · 2019-12-18

该研究基于澳大利亚昆士兰肿瘤在线登记库2000–2015年3636例非小细胞肺癌或小细胞肺癌病例,其中3352例有完整临床分期、1031例有完整病理分期,对比第八版与第七版TNM分期的预后区分度。结果显示中位生存期随临床和病理分期升高而缩短,生存曲线log-rank检验p<0.001,验证了第八版分期的预后准确性,但IIIB、IIIC和IVA期生存相似,提示需进一步细化。

要点

  • 第八版肺癌TNM分期在外部人群中验证了预后准确性。
  • 临床分期IA1中位生存未达到,IVB期仅3个月。
  • IIIB、IIIC与IVA期生存 outcomes 相似,建议进一步研究优化。

核心结论

  • 外部验证研究证实第八版肺癌TNM分期具有预后准确性。
  • 分析提示IIIB、IIIC和IVA期生存结果相似,建议进一步研究细化。

研究设计与样本

  • 基于昆士兰肿瘤在线登记库2000–2015年NSCLC或SCLC病例的验证研究。
  • 共3636例,其中3352例有完整临床分期,1031例有完整病理分期。
  • 使用病例识别号、姓名和出生日期与昆士兰综合肺癌结局项目登记库进行核对。
  • 按UICC第七版和第八版TNM分期分组比较,采用Kaplan-Meier曲线和log-rank检验(SPSS version 25)。

主要发现

  • 临床分期第七版中位生存期:IA 88个月、IB 44个月、IIA 31个月、IIB 18个月、IIIA 15个月、IIIB 8个月、IV 5个月。
  • 临床分期第八版中位生存期:IA1未达到、IA2 88个月、IA3 53个月、IB 56个月、IIA 36个月、IIB 22个月、IIIA 14个月、IIIB 9个月、IIIC 8个月、IVA 6个月、IVB 3个月。
  • 病理分期第七版中位生存期:IA 124个月、IB 110个月、IIA 48个月、IIB 42个月、IIIA 26个月、IIIB 31个月、IV 27个月。
  • 病理分期第八版中位生存期:IA1未达到、IA2 122个月、IA3 125个月、IB 144个月、IIA 98个月、IIB 57个月、IIIA 31个月、IIIB 24个月、IVA 7个月。
  • 生存曲线log-rank检验显著性为p < 0.001。

临床怎么用

  • 第八版TNM分期可用于肺癌预后评估和临床分期决策。
  • 对IIIB、IIIC和IVA期患者,需注意其生存相似性,个体化评估。

局限性

  • 研究基于单一机构登记库数据,外部推广需谨慎。
  • 部分病例分期数据不完整(临床分期3352例,病理分期1031例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We performed a validation study at our institution, the International Union Against Cancer (Union for International Cancer Control latest version of TNM Classification of Malignant Tumors Eighth Edition). METHODS: Data were collected from the Queensland Oncology Online registry of NSCLC or SCLC cases between 2000 and 2015 and validated against the Queensland Integrated Lung Cancer Outcomes Project registry using case identification number, first name, last name, and date of birth. Where data were available, cases were classified according to the Union for International Cancer Control TNM seventh edition stage groupings and then compared with the eighth edition groupings. Kaplan-Meier curves were plotted, and the log-rank test of survival differences was performed with SPSS version 25 (IBM Corp, Armonk, NY). RESULTS: Of the 3636 cases, 3352 and 1031 had complete clinical and pathologic staging, respectively. Median survival time was found to reduce with increasing clinical stage: seventh edition (IA: 88, IB: 44, IIA: 31, IIB: 18, IIIA: 15, IIIB: 8, and IV: 5 mo) versus eighth edition TNM stage (IA1: not reached, IA2: 88, IA3: 53, IB: 56, IIA: 36, IIB: 22, IIIA: 14, IIIB: 9, IIIC: 8, IVA: 6, and IVB: 3 mo). A similar overall pattern was reflected in the pathologic stage: seventh edition (IA: 124, IB: 110, IIA: 48, IIB: 42, IIIA: 26, IIIB: 31, and IV: 27 mo) versus eighth edition (IA1: not reached, IA2: 122, IA3: 125, IB: 144, IIA: 98, IIB: 57, IIIA: 31, IIIB: 24, and IVA: 7 mo). The log-rank test for survival curves was significant at p < 0.001. CONCLUSIONS: Our external validation study confirms the prognostic accuracy of the eighth edition TNM lung cancer classification. Our analyses also indicated that IIIB, IIIC, and IVA stage groups had similar survival outcomes and suggest further research for refinement.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hwang JK, Page BJ, Flynn D, et al. Validation of the Eighth Edition TNM Lung Cancer Staging System. J Thorac Oncol. 2019. PMID: 31863848. doi:10.1016/j.jtho.2019.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。